Health Imaging October 17, 2024
An artificial intelligence-based software developed to improve prostate cancer diagnostics recently proved its utility for reducing clinical workloads and improving patient outcomes.
The software—mdprostate (mediaire GmbH, Berlin, Germany)—is commercially available and CE marked. Experts recently integrated the tool into their organization’s PACS to apply it to a group of patients who underwent multiparametric prostate MRI. Their aim was to compare its performance to that of the radiologists who completed the exams’ initial interpretations. The team found that the software’s performance was in line with the rads, indicating that it could be beneficial in addressing issues with variability in reporting, experts involved in the analysis suggested.
“By providing objective assessments and standardizing lesion detection and classification, AI has the...
Today's Sponsors
Today's Sponsor